Department of Psychiatry and Health Behavior, Augusta University, Augusta, GA 30912, United States.
Clinical Development and Medical Affairs, Alkermes, Inc., Waltham, MA 02451, United States.
Schizophr Res. 2019 Jun;208:44-48. doi: 10.1016/j.schres.2019.01.038. Epub 2019 Feb 7.
We assessed the effectiveness of switching from paliperidone palmitate (PP) or risperidone long-acting injection (RLAI) to aripiprazole lauroxil (AL). Prospective, 6-month study in patients with schizophrenia with residual symptoms or intolerance with PP/RLAI. Effectiveness assessed via all-cause and medication-related discontinuation; CGI-S/BPRS and adverse event monitoring assessed efficacy/tolerability, respectively. Fifty-one patients (n = 50 PP; n = 1 RLAI) enrolled; 35 completed the study. All-cause and medication-related discontinuation was 30% and 9% over 6 months, respectively. CGI-S/BPRS improved significantly in those continuing treatment. Adverse events were generally mild to moderate. Patients with efficacy or tolerability concerns with PP/RLAI can be switched to AL.
我们评估了将帕利哌酮棕榈酸酯（PP）或利培酮长效注射剂（RLAI）转换为阿立哌唑月桂酰酯（AL）的效果。这是一项针对精神分裂症患者的前瞻性、6 个月研究，这些患者存在残留症状或对 PP/RLAI 不耐受。通过全因和与药物相关的停药评估有效性；CGI-S/BPRS 和不良反应监测分别评估疗效/耐受性。共有 51 名患者（n=50 名 PP；n=1 名 RLAI）入组；35 名患者完成了研究。6 个月时，全因和与药物相关的停药率分别为 30%和 9%。继续治疗的患者 CGI-S/BPRS 显著改善。不良反应通常为轻度至中度。对于那些对 PP/RLAI 有疗效或耐受性问题的患者，可以将其转换为 AL。
